Thermo Fisher Scientific Expands its Global Biologics and Steriles Manufacturing Capabilities in China
Search Patheon
Recent searches
Clear History
Suggestions
All Results
Recent searches
Clear History
Suggestions
All Results
Search
US | EN
Pharmaceutical companies walk a tightrope in early drug development. They have to balance speed, quality, scientific risk, and API cost. Compromising on any one of these four crucial elements can prove fatal to a product candidate. Appropriate use of sound science applied at critical junctures will improve efficiency in the high-wire act of drug development.
Author: Anil Kane, Ph.D., MBA